Skip to main content
Fig. 4 | Journal of Biomedical Science

Fig. 4

From: Antibody cocktail effective against variants of SARS-CoV-2

Fig. 4

Therapeutic effects of neutralizing RBD-chAbs against SARS-CoV-2 infection. A, B, One day after to intranasal (i.n.) challenge of WT SARS-CoV-2, each group of hamsters was given a single intraperitoneal injection of 3 mg/kg RBD-chAb-15 (n = 4), 3 mg/kg RBD-chAb-45 (n = 4), a total of 3 mg/kg RBD-chAb-15 combined with RBD-chAb-45 (n = 4), or 3 mg/kg NHIgG isotype control (n = 4). C, D, One day after to intranasal (i.n.) challenge with Delta SARS-CoV-2 variant, each group of hamsters was given a single intraperitoneal injection. Injections contained: 6 mg/kg RBD-chAb-45 (n = 6), a total of 6 mg/kg RBD-chAb-15 combined with RBD-chAb-45 (n = 6), a total of 6 mg/kg RBD-chAb-28 combined with RBD-chAb-45 (n = 6), or 6 mg/kg NHIgG isotype control (n = 6). A and C, On day 3 after virus inoculation, the viral load in the lungs of treated hamsters was determined by qRT-PCR. B, D On day 3 after virus inoculation, the viral load in the lungs of treated hamsters was determined by median tissue culture infectious dose per ml (TCID50/ml). Statistical differences were determined by two-tailed Student t test. *P < 0.05, ***P < 0.001

Back to article page